It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The current lack of a reliable biomarker of disease activity in anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis poses a significant clinical unmet need when determining relapsing or persisting disease. In this study, we demonstrate for the first time that attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy offers a novel and functional candidate biomarker, distinguishing active from quiescent disease with a high degree of accuracy. Paired blood and urine samples were collected within a single UK centre from patients with active disease, disease remission, disease controls and healthy controls. Three key biofluids were evaluated; plasma, serum and urine, with subsequent chemometric analysis and blind predictive model validation. Spectrochemical interrogation proved plasma to be the most conducive biofluid, with excellent separation between the two categories on PC2 direction (AUC 0.901) and 100% sensitivity (F-score 92.3%) for disease remission and 85.7% specificity (F-score 92.3%) for active disease on blind predictive modelling. This was independent of organ system involvement and current ANCA status, with similar findings observed on comparative analysis following successful remission-induction therapy (AUC > 0.9, 100% sensitivity for disease remission, F-score 75%). This promising technique is clinically translatable and warrants future larger study with longitudinal data, potentially aiding earlier intervention and individualisation of treatment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Royal Preston Hospital, Lancashire NHS Foundation Trust, Department of Renal Medicine, Preston, UK (GRID:grid.416204.5) (ISNI:0000 0004 0391 9602)
2 University of Central Lancashire, School of Pharmacy and Biomedical Sciences, Preston, UK (GRID:grid.7943.9) (ISNI:0000 0001 2167 3843)
3 Federal University of Rio Grande Do Norte, Institute of Chemistry, Biological Chemistry and Chemometrics, Natal, Brazil (GRID:grid.411233.6) (ISNI:0000 0000 9687 399X)
4 Royal Preston Hospital, Lancashire NHS Foundation Trust, Department of Immunology, Preston, UK (GRID:grid.416204.5) (ISNI:0000 0004 0391 9602); University of Central Lancashire, School of Medicine, Preston, UK (GRID:grid.7943.9) (ISNI:0000 0001 2167 3843)
5 Biocel UK Ltd, Hull, UK (GRID:grid.7943.9)